111 related articles for article (PubMed ID: 37283969)
1. Safety and immunogenicity of an
Chu K; Bi ZF; Huang WJ; Li YF; Zhang L; Yang CL; Jiang HM; Zang X; Chen Q; Liu DL; Pan HX; Huang Y; Zheng FZ; Zhang QF; Sun G; Su YY; Huang SJ; Pan HR; Wu T; Hu YM; Zhang J; Zhu FC; Xia NS
Lancet Reg Health West Pac; 2023 May; 34():100731. PubMed ID: 37283969
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial.
Hu YM; Bi ZF; Zheng Y; Zhang L; Zheng FZ; Chu K; Li YF; Chen Q; Quan JL; Hu XW; Huang XC; Zhu KX; Wang-Jiang YH; Jiang HM; Zang X; Liu DL; Yang CL; Pan HX; Zhang QF; Su YY; Huang SJ; Sun G; Huang WJ; Huang Y; Wu T; Zhang J; Xia NS
Sci Bull (Beijing); 2023 Oct; 68(20):2448-2455. PubMed ID: 37743201
[TBL] [Abstract][Full Text] [Related]
3. Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial.
Zhu FC; Zhong GH; Huang WJ; Chu K; Zhang L; Bi ZF; Zhu KX; Chen Q; Zheng TQ; Zhang ML; Liu S; Xu JB; Pan HX; Sun G; Zheng FZ; Zhang QF; Yi XM; Zhuang SJ; Huang SJ; Pan HR; Su YY; Wu T; Zhang J; Xia NS
Lancet Infect Dis; 2023 Nov; 23(11):1313-1322. PubMed ID: 37475116
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of an
Mo ZJ; Bi ZF; Sheng W; Chen Q; Huang T; Li MQ; Cui XL; Wangjiang YH; Lin BZ; Zheng FZ; Sun G; Li YF; Zheng Y; Zhuang SJ; Su YY; Pan HR; Huang SJ; Wu T; Zhang J; Xia NS
Hum Vaccin Immunother; 2022 Nov; 18(6):2092363. PubMed ID: 35834812
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial.
Zhao FH; Wu T; Hu YM; Wei LH; Li MQ; Huang WJ; Chen W; Huang SJ; Pan QJ; Zhang X; Hong Y; Zhao C; Li Q; Chu K; Jiang YF; Li MZ; Tang J; Li CH; Guo DP; Ke LD; Wu X; Yao XM; Nie JH; Lin BZ; Zhao YQ; Guo M; Zhao J; Zheng FZ; Xu XQ; Su YY; Zhang QF; Sun G; Zhu FC; Li SW; Li YM; Pan HR; Zhang J; Qiao YL; Xia NS
Lancet Infect Dis; 2022 Dec; 22(12):1756-1768. PubMed ID: 36037823
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial.
Thiem VD; Quang ND; Tuan NH; Cheon K; Gallagher N; Luxembourg A; Group T; Badshah C
Hum Vaccin Immunother; 2021 Jul; 17(7):1980-1985. PubMed ID: 33844623
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a skin- and neuro-attenuated live vaccine for varicella: a randomized, double-blind, controlled, dose-escalation and age de-escalation phase 1 clinical trial.
Mo ZJ; Huang SJ; Qiu LX; Li CG; Yu XJ; Li MQ; Chen Z; Zhong GH; Pan DQ; Huang LR; Lv BJ; Cui XL; Song QQ; Jia JZ; Han JL; Wang W; Zhu H; Cheng T; Su YY; Li YM; Ye XZ; Wu T; Zhang J; Xia NS
Lancet Reg Health West Pac; 2023 May; 34():100707. PubMed ID: 37283962
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9-45 years of age: A phase 3 open-label study.
Lv H; Wang S; Liang Z; Yu W; Yan C; Chen Y; Hu X; Fu R; Zheng M; Group T; Luxembourg A; Liao X; Chen Z
Vaccine; 2022 May; 40(23):3263-3271. PubMed ID: 35487814
[TBL] [Abstract][Full Text] [Related]
12. Lot-to-lot consistency study of an
Su YY; Lin BZ; Zhao H; Li J; Lin ZJ; Qiao YL; Wei LH; Hu YM; Li RC; Zhuang SJ; Sun G; Zheng ZZ; Huang SJ; Wu T; Zhang J; Pan HR; Li CG
Hum Vaccin Immunother; 2020 Jul; 16(7):1636-1644. PubMed ID: 31770068
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Wu Z; Hu Y; Xu M; Chen Z; Yang W; Jiang Z; Li M; Jin H; Cui G; Chen P; Wang L; Zhao G; Ding Y; Zhao Y; Yin W
Lancet Infect Dis; 2021 Jun; 21(6):803-812. PubMed ID: 33548194
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial.
Han B; Song Y; Li C; Yang W; Ma Q; Jiang Z; Li M; Lian X; Jiao W; Wang L; Shu Q; Wu Z; Zhao Y; Li Q; Gao Q
Lancet Infect Dis; 2021 Dec; 21(12):1645-1653. PubMed ID: 34197764
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial.
Landier W; Bhatia S; Wong FL; York JM; Flynn JS; Henneberg HM; Singh P; Adams K; Wasilewski-Masker K; Cherven B; Jasty-Rao R; Leonard M; Connelly JA; Armenian SH; Robison LL; Giuliano AR; Hudson MM; Klosky JL
Lancet Child Adolesc Health; 2022 Jan; 6(1):38-48. PubMed ID: 34767765
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial.
Gilca V; Sauvageau C; Panicker G; De Serres G; Ouakki M; Unger ER
Vaccine; 2018 Nov; 36(46):7017-7024. PubMed ID: 30314913
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.
Zeng G; Wu Q; Pan H; Li M; Yang J; Wang L; Wu Z; Jiang D; Deng X; Chu K; Zheng W; Wang L; Lu W; Han B; Zhao Y; Zhu F; Yu H; Yin W
Lancet Infect Dis; 2022 Apr; 22(4):483-495. PubMed ID: 34890537
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9-45 years: A randomized, double-blind, placebo-controlled phase 1 clinical trial.
Li J; Shi LW; Yu BW; Huang LR; Zhou LY; Shi L; Jiang ZW; Xia JL; Wang XY; Li RC; Yuan L; Li YP; Li CG
Vaccine; 2023 May; 41(19):3141-3149. PubMed ID: 37061370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
